Should I buy or sell Fortress Biotech stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FBIO shares. View FBIO analyst ratings or view top-rated stocks .

What is Fortress Biotech's stock price target for 2024?

3 brokers have issued 1-year price targets for Fortress Biotech's stock. Their FBIO share price targets range from $5.00 to $75.00. On average, they predict the company's stock price to reach $30.00 in the next year. This suggests a possible upside of 1,614.3% from the stock's current price. View analysts price targets for FBIO or view top-rated stocks among Wall Street analysts .

How have FBIO shares performed in 2024?

Fortress Biotech's stock was trading at $3.01 on January 1st, 2024. Since then, FBIO stock has decreased by 41.9% and is now trading at $1.75. View the best growth stocks for 2024 here .

Are investors shorting Fortress Biotech?

Fortress Biotech saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 1,880,000 shares, an increase of 8.7% from the March 15th total of 1,730,000 shares. Based on an average daily volume of 392,200 shares, the short-interest ratio is currently 4.8 days. Currently, 14.1% of the shares of the stock are sold short. View Fortress Biotech's Short Interest .

When is Fortress Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our FBIO earnings forecast .

How were Fortress Biotech's earnings last quarter?

Fortress Biotech, Inc. (NASDAQ:FBIO) announced its quarterly earnings data on Monday, November, 15th. The biopharmaceutical company reported ($2.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.20) by $0.90. The biopharmaceutical company had revenue of $21.09 million for the quarter, compared to analysts' expectations of $18.41 million. Fortress Biotech had a negative trailing twelve-month return on equity of 770.86% and a negative net margin of 74.12%.

When did Fortress Biotech's stock split?

Fortress Biotech's stock reverse split on the morning of Tuesday, October 10th 2023. The 1-15 reverse split was announced on Monday, October 9th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Fortress Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fortress Biotech investors own include Sorrento Therapeutics (SRNE) , VBI Vaccines (VBIV) , Novavax (NVAX) , Advanced Micro Devices (AMD) , OPKO Health (OPK) , TG Therapeutics (TGTX) , Vaxart (VXRT) , NVIDIA (NVDA) , Pfizer (PFE) and Dynavax Technologies (DVAX) .

How do I buy shares of Fortress Biotech?

Shares of FBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:FBIO

Fortress Biotech (FBIO) Stock Price, News & Analysis

→ Urgent alert: open this for a huge profit potential (From Timothy Sykes) (Ad)

Free FBIO Stock Alerts

$1.75

-0.06 (-3.31%)

(As of 04/19/2024 ET)

Compare

Today's Range: $1.71
▼
$1.86
50-Day Range: $1.68
▼
$2.43
52-Week Range: $1.24
▼
$12.00

Volume: 186,235 shs
Average Volume: 406,387 shs
Market Capitalization: $33.66 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $30.00

Get Fortress Biotech alerts:

Fortress Biotech MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,614.3% Upside
$30.00 Price Target
Short Interest: Bearish
14.08% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($6.57) to ($5.57) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.28 out of 5 stars

Medical Sector

433rd out of 911 stocks

Pharmaceutical Preparations Industry

192nd out of 411 stocks

3.5

Analyst's Opinion

Consensus Rating
Fortress Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Fortress Biotech has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
14.08% of the float of Fortress Biotech has been sold short.
Short Interest Ratio / Days to Cover
Fortress Biotech has a short interest ratio ("days to cover") of 4.8.
Change versus previous month
Short interest in Fortress Biotech has recently increased by 8.67%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Fortress Biotech does not currently pay a dividend.
Dividend Growth
Fortress Biotech does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for FBIO.

2.7

News and Social Media Coverage

News Sentiment
Fortress Biotech has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Fortress Biotech this week, compared to 1 article on an average week.
Search Interest
Only 15 people have searched for FBIO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
29 people have added Fortress Biotech to their MarketBeat watchlist in the last 30 days. This is an increase of 4% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Fortress Biotech insiders have not sold or bought any company stock.
Percentage Held by Insiders
33.40% of the stock of Fortress Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
96.51% of the stock of Fortress Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Fortress Biotech are expected to grow in the coming year, from ($6.57) to ($5.57) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Fortress Biotech is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Fortress Biotech is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Fortress Biotech has a P/B Ratio of 17.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Timothy Sykes

Urgent alert: open this for a huge profit potential

This groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo, or CNBC.

See Tim’s instructions to make this remarkably simple trade right here

About Fortress Biotech Stock (NASDAQ:FBIO)

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

FBIO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

FBIO Stock News Headlines

April 13, 2024 | americanbankingnews.com

Research Analysts Set Expectations for Fortress Biotech, Inc.'s Q1 2024 Earnings (NASDAQ:FBIO)

April 12, 2024 | americanbankingnews.com

Fortress Biotech, Inc. to Post FY2027 Earnings of ($6.67) Per Share, HC Wainwright Forecasts (NASDAQ:FBIO)

April 20, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

April 12, 2024 | americanbankingnews.com

Fortress Biotech (NASDAQ:FBIO) Downgraded to Sell at StockNews.com

April 11, 2024 | investorplace.com

3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024

March 29, 2024 | finanznachrichten.de

Fortress Biotech, Inc.: Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights

March 28, 2024 | globenewswire.com

Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights

March 28, 2024 | finanznachrichten.de

Mustang Bio, Inc.: Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

April 20, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

March 28, 2024 | msn.com

Mustang Bio stock climbs 9% amid drug development update

March 22, 2024 | globenewswire.com

Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

March 21, 2024 | globenewswire.com

Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

March 18, 2024 | finance.yahoo.com

Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights

March 18, 2024 | globenewswire.com

Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea

March 15, 2024 | globenewswire.com

Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024

March 13, 2024 | globenewswire.com

Journey Medical Corporation to Participate in the 36th Annual ROTH Conference

March 12, 2024 | globenewswire.com

Fortress Biotech to Participate in 36th Annual ROTH Conference

March 11, 2024 | globenewswire.com

Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting

March 4, 2024 | globenewswire.com

Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease

January 29, 2024 | finance.yahoo.com

Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market

January 11, 2024 | finance.yahoo.com

Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference

January 9, 2024 | finance.yahoo.com

Insider Buying: President, CEO & Chairman, 10% Owner ROSENWALD LINDSAY A MD Acquires 50,000 ...

January 5, 2024 | finance.yahoo.com

Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea

January 5, 2024 | finance.yahoo.com

Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds

January 4, 2024 | finance.yahoo.com

Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol

January 2, 2024 | finance.yahoo.com

Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

December 29, 2023 | markets.businessinsider.com

Why Fortress Biotech Shares Are Tumbling Today

See More Headlines

Receive FBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fortress Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/15/2021
Today: 4/20/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:FBIO
CUSIP: 21976U10
CIK: 1429260
Web: www.fortressbiotech.com
Phone: (781) 652-4500
Fax: 781-652-4545
Employees: 187
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $30.00
High Stock Price Target: $75.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +1,614.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($8.22)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-60,640,000.00
Net Margins: -74.12%
Pretax Margin: -181.79%
Return on Equity: -770.86%
Return on Assets: -32.87%

Debt

Debt-to-Equity Ratio: 38.42
Current Ratio: 1.38
Quick Ratio: 1.26

Sales & Book Value

Annual Sales: $84.51 million
Price / Sales: 0.40
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.10 per share
Price / Book: 17.50

Miscellaneous

Outstanding Shares: 19,235,000
Free Float: 12,811,000
Market Cap: $33.66 million
Optionable: Optionable
Beta: 1.51

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Dr. Lindsay Allan Rosenwald (Age 69)
Executive Chairman, President & CEO
Comp: $942.78k
Mr. Michael S. Weiss Esq. (Age 58)
Vice Chairman & Executive Vice Chairman of Strategic Development
Comp: $167.92k
Mr. David Jin (Age 33)
CFO & Head of Corporate Development
Comp: $976.96k
Dr. George C. Avgerinos (Age 70)
Senior Vice President of Biologics Operations
Comp: $386.49k
Mr. Samuel Berry
General Counsel & Corporate Secretary

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

FBIO Stock Analysis - Frequently Asked Questions

Should I buy or sell Fortress Biotech stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FBIO shares.
View FBIO analyst ratings or view top-rated stocks.
What is Fortress Biotech's stock price target for 2024?: 3 brokers have issued 1-year price targets for Fortress Biotech's stock. Their FBIO share price targets range from $5.00 to $75.00. On average, they predict the company's stock price to reach $30.00 in the next year. This suggests a possible upside of 1,614.3% from the stock's current price.
View analysts price targets for FBIO or view top-rated stocks among Wall Street analysts.
How have FBIO shares performed in 2024?: Fortress Biotech's stock was trading at $3.01 on January 1st, 2024. Since then, FBIO stock has decreased by 41.9% and is now trading at $1.75.
View the best growth stocks for 2024 here.
Are investors shorting Fortress Biotech?: Fortress Biotech saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 1,880,000 shares, an increase of 8.7% from the March 15th total of 1,730,000 shares. Based on an average daily volume of 392,200 shares, the short-interest ratio is currently 4.8 days. Currently, 14.1% of the shares of the stock are sold short.
View Fortress Biotech's Short Interest.
When is Fortress Biotech's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our FBIO earnings forecast.

How were Fortress Biotech's earnings last quarter?: Fortress Biotech, Inc. (NASDAQ:FBIO) announced its quarterly earnings data on Monday, November, 15th. The biopharmaceutical company reported ($2.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.20) by $0.90. The biopharmaceutical company had revenue of $21.09 million for the quarter, compared to analysts' expectations of $18.41 million. Fortress Biotech had a negative trailing twelve-month return on equity of 770.86% and a negative net margin of 74.12%.
When did Fortress Biotech's stock split?: Fortress Biotech's stock reverse split on the morning of Tuesday, October 10th 2023. The 1-15 reverse split was announced on Monday, October 9th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
What other stocks do shareholders of Fortress Biotech own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Fortress Biotech investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Novavax (NVAX), Advanced Micro Devices (AMD), OPKO Health (OPK), TG Therapeutics (TGTX), Vaxart (VXRT), NVIDIA (NVDA), Pfizer (PFE) and Dynavax Technologies (DVAX).
How do I buy shares of Fortress Biotech?: Shares of FBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FBIO) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial